AZA drug reactions were common but infrequently severe or symptomatic. Higher comorbidity burden predicted drug reactions. Most laboratory abnormalities resolved without AZA discontinuation, supporting individualized monitoring and dose adjustment rather than automatic cessation. Lower doses should be considered for balancing efficacy with dose-dependent drug reactions.
Gaini et al. (Wed,) studied this question.